Industries > Pharma > Anti-infective Vaccines Market Report to 2031
Anti-infective Vaccines Market Report to 2031
By product (Live/attenuated Vaccines, Inactivated Vaccines, Conjugate vaccines, toxoid vaccine, Others) by Disease Type Bacterial diseases (Tuberculosis vaccine, Typhoid vaccine, Diphtheria and Tetanus Vaccines, Others) Viral Diseases (Influenza vaccine, Hepatitis vaccine, Polio vaccine, Others) by End Users (Hospitals, Clinics, Others) and Leading Regional/ Country market analysis
Anti-Infective Vaccines Market– our new study reveals trends, R&D progress, and predicted revenues
Where is the Anti-Infective Vaccines market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our Anti-Infective Vaccines report provides tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Anti-Infective Vaccines Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
Anti-Infective Vaccines Market by product
• Live/attenuated Vaccines
• Inactivated Vaccines
• Conjugate vaccines
• toxoid vaccines
• Others
Anti-Infective Vaccines Market by Disease Type
• Bacterial diseases
o Tuberculosis vaccine
o Typhoid vaccine
o Diphtheria and Tetanus vaccines
o Others
• Viral Diseases
o Influenza vaccine
o Hepatitis vaccine
o Polio vaccine
o Others
Anti-Infective Vaccines Market by End Users
• Hospitals
• Clinics
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 16 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Japan
o Rest of Asia Pacific
• Latin America
o Rest of Latin America
• Middle East
o Rest of Middle East
The report also includes profiles and for some of the leading companies in the Anti-Infective Vaccines Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Anti-Infective Vaccines Market with forecasts for product type, disease type and End-User, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Anti-Infective Vaccines Market report helps you
In summary, our 321 page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Anti-Infective Vaccines Market, with forecasts by Product type, Disease type, and End User, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2030 for 5 regional and 16 key national markets – See forecasts for the Anti-Infective Vaccines market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Rest of Asia Pacific, Latin America and Middle East and Africa among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for Anti-Infective Vaccinesof the major companies involved in the Anti-Infective Vaccines Market. Some of the company’s profiled in this report include-
• Pfizer Inc.
• Merck & Co.
• Sanofi Pasteur Inc.
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline Biologicals,
• Emergent Biosolutions
• AstraZeneca
• Organon Teknika Corp LLC,
• Emergent BioDefense Operations Lansing Inc.
• MedImmune LLC,
• Novartis Vaccines
• Serum Institute Of India Pvt. Ltd.
• Protein Sciences Corporation
• Diagnostics Ltd.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the global Anti-Infective Vaccines Market and leading companies. You will find data, trends, and predictions.
Get our report today Anti-Infective Vaccines Market Report to 2031: By product (Live/attenuated Vaccines, Inactivated Vaccines, Conjugate vaccines, toxoid vaccine, Others) by Disease Type Bacterial diseases (Tuberculosis vaccine, Typhoid vaccine, Diphtheria and Tetanus Vaccines, Others) Viral Diseases (Influenza vaccine, Hepatitis vaccine, Polio vaccine, Others) by End Users (Hospitals, Clinics, Others) and Leading Regional/ Country market analysis.
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Anti-Infective Vaccines Market
2.1. Anti-Infective Vaccines Market Definition
2.2. By Product type Submarkets Definitions
2.3. By Disease type Submarkets Definitions
2.4. By End User Submarkets Definitions
3. Anti-Infective Vaccines Market Overview
3.1. Global Anti-Infective Vaccines Market Size and Forecast by Region
3.2. Global Anti-Infective Vaccines Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising Awareness for Infectious Diseases.
3.3.1.2. Priority Review Vouchers (PRVs), Development of New Vaccines for Infectious Diseases.
3.3.1.3. Rising Prevalence of Infectious Diseases.
3.3.2. Market Restraints/Challenges
3.3.2.1. High Cost Associated With R&D
3.3.2.2. Inadequate Funding of Healthcare in Developing Countries
3.3.3. Opportunities
3.3.3.1. Increasing Old Age Population.
3.3.3.2. Growing Health Awareness Among Population
3.3.3.3. Rising Disposable Income in Emerging Economies
3.3.3.4. Increasing Demand of Anti -Infective Vaccine Market
3.3.4. Global Anti-Infective Vaccines Market: Trends
3.3.4.1. Increasing Immunization Programmes.
3.3.4.2. Advancement in Healthcare Sector.
3.3.5. Porter’s Five Forces Analysis
3.3.5.1. Competitive Rivalry
3.3.5.2. Supplier Power
3.3.5.3. Buyer Power
3.3.5.4. Threat of Substitution
3.3.5.5. Threat of New Entry
4. Global Anti-Infective Vaccines Market Analysis and Forecast 2021-2031, by Product type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Live/attenuated Vaccines
4.1.1.1. Provides lifelong immunity one or two doses.
4.2. Inactivated Vaccines
4.2.1.1. Easy to store and freeze dried.
4.3. Conjugate vaccines
4.3.1.1. Low risk of adverse reaction.
4.4. toxoid vaccines
4.4.1.1. specifically used for Diphtheria and Tetanus.
4.5. Others
5. Global Anti-Infective Vaccines Market Analysis and Forecast, 2021-2031 by Disease type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Bacterial diseases
5.1.1.1. Tuberculosis vaccine
5.1.1.2. Tuberculosis is the leading cause of death among women.
5.1.1.3. Typhoid vaccine
5.1.1.4. Increasing typhoid in developing countries.
5.1.1.5. Diphtheria and Tetanus vaccines
5.1.1.6. DTaP vaccine, DT vaccine, Tdap vaccine and Td vaccine protects from Diphtheria and tetanus.
5.1.1.7. Others
5.1.2. Viral Diseases
5.1.2.1. Influenza vaccine
5.1.2.2. High risk of influenzas among elderly.
5.1.2.3. Hepatitis vaccine
5.1.2.4. RECOMBIVAX HB vaccine prevents from infection caused by subtypes of hepatitis B virus.
5.1.2.5. Polio vaccine
5.1.2.6. Increasing awareness and immunization campaigns.
5.1.2.7. Others
6. Global Anti-Infective Vaccines Market Analysis and Forecast, 2021-2031 by end user (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Hospitals
6.1.1.1. Increasing hospitalization among elderly due to risk infectious diseases.
6.1.2. Clinics
6.1.2.1. Rising adoption of Anti-Infective Vaccines in clinics & hospitals
6.1.3. Others
7. North America Anti-Infective Vaccines Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Anti-Infective Vaccines Market Size and Forecast by Product type
7.2.1. Live/attenuated Vaccines Submarket Expected to Grow at Significant Rate
7.3. North America Anti-Infective Vaccines Market Size and Forecast by Disease type
7.3.1. Bacterial disease Submarket to Grow at Significant Rate
7.4. North America Anti-Infective Vaccines Market Size and Forecast by end user
7.4.1. Hospitals Submarket to Grow at Significant Rate
7.5. U.S. Anti-Infective Vaccines Market
7.5.1. Developed Healthcare System.
7.6. Canada Anti-Infective Vaccines Market
7.6.1. Growing demand for infectious diseases vaccine.
8. Europe Anti-Infective Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Anti-Infective Vaccines Market Size and Forecast by Product type
8.2.1. Live/attenuated Vaccines Submarket Expected to Grow at Significant Rate
8.3. Europe Anti-Infective Vaccines Market Size and Forecast by Disease type
8.3.1. Bacterial disease Submarket to Grow at Significant Rate
8.4. Europe Anti-Infective Vaccines Market Size and Forecast by end user
8.4.1. Hospitals Submarket to Grow at Significant Rate
8.5. UK Anti-Infective Vaccines Market
8.5.1. Increasing multidrug-resistant among tuberculosis patients.
8.6. Germany Anti-Infective Vaccines Market
8.6.1. Surging demand for anti-infective vaccine in the region.
8.7. France Anti-Infective Vaccines Market
8.7.1. Presence of key market players are expected to drive market growth.
8.8. Rest of Europe Anti-Infective Vaccines Market
9. Asia Pacific Anti-Infective Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Anti-Infective Vaccines Market Size and Forecast by Product type
9.2.1. Live/attenuated Vaccines Submarket Expected to Grow at Significant Rate
9.3. Asia Pacific Anti-Infective Vaccines Market Size and Forecast by Disease type
9.3.1. Bacterial disease Submarket to Grow at Significant Rate
9.4. Asia Pacific Anti-Infective Vaccines Market Size and Forecast by end user
9.4.1. Hospitals Submarket to Grow at Significant Rate
9.5. China Anti-Infective Vaccines Market
9.5.1. Rising elderly population
9.6. India Anti-Infective Vaccines Market
9.6.1. Prevalence of infectious diseases.
9.7. Japan Anti-Infective Vaccines Market
9.7.1. Increasing healthcare awareness
9.8. Rest of Asia Pacific Anti-Infective Vaccines Market
10. Latin America Anti-Infective Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Anti-Infective Vaccines Market Size and Forecast by Product type
10.2.1. Live/attenuated Vaccines Submarket Expected to Grow at Significant Rate
10.3. Latin America Anti-Infective Vaccines Market Size and Forecast by Disease type
10.3.1. Bacterial disease Submarket to Grow at Significant Rate
10.4. Latin America Anti-Infective Vaccines Market Size and Forecast by end user
10.4.1. Brazil Anti-Infective Vaccines Market
10.4.1.1. Increasingly risk for acute respiratory infections.
10.4.2. Mexico Anti-Infective Vaccines Market
10.4.2.1. Prevalence of infectious diseases.
10.4.3. Rest of Latin America Anti-Infective Vaccines Market
10.4.3.1. Increasing government initiatives for immunization.
11. MEA Anti-Infective Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Anti-Infective Vaccines Market Size and Forecast by Product type
11.2.1. Live/attenuated Vaccines Submarket Expected to Grow at Significant Rate
11.3. MEA Anti-Infective Vaccines Market Size and Forecast by Disease type
11.3.1. Bacterial disease Submarket to Grow at Significant Rate
11.4. MEA Anti-Infective Vaccines Market Size and Forecast by end user
11.5. South Africa Anti-Infective Vaccines Market
11.5.1.1. Increasing risk of HIV in the population.
11.6. Rest of MEA Anti-Infective Vaccines Market
11.6.1.1. Increasingly healthcare awareness and vaccination for infectious diseases.
12. Companies in the Anti-Infective Vaccines Market
12.1. Pfizer Inc.
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2020)
12.1.3.1. Net Revenue
12.1.3.2. Gross Profit
12.1.3.3. Geographical Revenue, 2020
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2020)
12.2. Merck & Co.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Gross Profit
12.2.3.3. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. Sanofi Pasteur Inc.
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. Teva Pharmaceutical Industries Ltd.
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. GlaxoSmithKline Biologicals,
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Emergent Biosolutions Inc.
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Gross Profit
12.6.3.3. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. AstraZeneca
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Gross Profit
12.7.3.3. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. Organon Teknika Corp LLC,
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Gross Profit
12.8.3.3. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Emergent BioDefense Operations Lansing Inc.
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Gross Profit
12.9.3.3. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. MedImmune LLC,
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Gross Profit
12.10.3.3. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Anti-Infective Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Anti-Infective Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Anti-Infective Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Anti-Infective Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Anti-Infective Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Anti-Infective Vaccines Market Drivers & Restraints 2021
Table 7. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Conjugate vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Conjugate vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Toxoid vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Toxoid vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Toxoid vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Toxoid vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Toxoid vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Other Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Other Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Other Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Other Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Other Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32 .Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 33. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Bacterial disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Bacterial disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Bacterial disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Bacterial disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Bacterial disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Tuberculosis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Tuberculosis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Tuberculosis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Tuberculosis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Tuberculosis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Typhoid vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Typhoid vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Typhoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Typhoid vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Typhoid vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Diphtheria and Tetanus Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Diphtheria and Tetanus Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Diphtheria and Tetanus Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Diphtheria and Tetanus Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Diphtheria and Tetanus Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Viral Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Viral Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Viral Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Viral Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Viral Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Influenza vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Influenza vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Influenza vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Influenza vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Influenza vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Hepatitis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Hepatitis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74 Hepatitis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Hepatitis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Hepatitis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Polio Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Polio Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table79. Polio Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Polio Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Polio Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Anti-Infective Vaccines Market Forecast by end user 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Anti-Infective Vaccines Market Forecast by end user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Anti-Infective Vaccines Market Forecast by end user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Anti-Infective Vaccines Market Forecast by end user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Anti-Infective Vaccines Market Forecast by end user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 120. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 121. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 122. North America Anti-Infective Vaccines Market Forecast by End User2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 123. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 124. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 125. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 126. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 127. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 128. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 129. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 130. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 131. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 132. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 133. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 134. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 135. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 136. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 137. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 138. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 139. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 140. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 141. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 142. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 143. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 144. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 145. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 146. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 147. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 148. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 149. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 150. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 151. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 152. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 153. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 154. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 155. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 156. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 157. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 158. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 159. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 160. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 161. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 162. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 163. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 164. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 165. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 166. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 167. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 168. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 169. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 170. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 171. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 172. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 173. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %CAGR %) (Before COVID)
Table 174.FranceAnti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %CAGR %), (COVID - Scenario W)
Table 175. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 176. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 177. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 178. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 179. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 180. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 181. Asia Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 182. Asia Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 183. Asia Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 184. Asia Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 185. Asia Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 186. Asia Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 187. Asia Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 188. Asia Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 189. Asia Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 190. Asia Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 191. Asia Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 192. Asia Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 193. Asia Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 194. Asia Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 195. Asia Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 196. Asia Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 197. Asia Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198. Asia Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199. Asia Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200. Asia Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216. RoAPAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217. RoAPAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218. RoAPAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219. RoAPAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220. RoAPAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224 Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231 Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232 Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 247. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248 Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251 Leading 10 Anti-Infective Vaccines Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 252. Pfizer Inc Profile 2020 (CEO, HQ, Founded, Website)
Table 253. Pfizer Inc Anti-Infective Vaccines Selected Recent Contracts 2020 (Date, Programme Type, Details)
Table 254. Pfizer Inc Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 255. Merck & Co. Profile 2020 (CEO, HQ, Founded, Website)
Table 256. Merck & Co Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 257. Sanofi Pasteur Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 258. Sanofi Pasteur Inc. Anti-Infective Vaccines Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 259. Sanofi Pasteur Inc. Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 260. Teva Pharmaceutical Industries Ltd Profile 2020 (CEO, HQ, Founded, Website)
Table 261. Teva Pharmaceutical Industries Ltd Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 262. Teva Pharmaceutical Industries Ltd Anti-Infective Vaccines Parasiticides Product Offering (Segment, Product Offerings)
Table 263. GlaxoSmithKline Biologicals, Profile 2020 (CEO, HQ, Founded, Website)
Table 264. GlaxoSmithKline Biologicals Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 265. Emergent Biosolutions Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 266. Emergent Biosolutions Inc Anti-Infective Vaccines Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 267 Emergent Biosolutions Inc Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 268. AstraZeneca Profile 2020 (CEO, HQ, Founded, Website)
Table 269. AstraZeneca. Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 270. Organon Teknika Corp LLC, Profile 2020 (CEO, HQ, Founded, Website)
Table 271. Organon Teknika Corp LLC, Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 272. Emergent BioDefense Operations Lansing Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 273. Emergent BioDefense Operations Lansing Inc.Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 274. MedImmune LLC Profile 2020 (CEO, Total Company Sales US$m, HQ, Founded, No. of Employees, Ticker, Website)
Table 275. MedImmune LLC Total Company Sales 2015-2019 (US$m, AGR %)
Table 276. MedImmune LLC Product Offering (Segment, Product Offerings)
Table 277. Other Companies Involved in the Anti-Infective Vaccines Market (Company, Location)
LIST OF FIGURES
Figure 1. Anti-Infective Vaccines Market Type Overview
Figure 2. Anti-Infective Vaccines Market By Product type Overview
Figure 3. Anti-Infective Vaccines Market By Disease type Overview
Figure4. Anti-Infective Vaccines Market End User Overview
Figure 5 Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 16. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID – Scenario V)
Figure 17. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 18. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 19. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 20. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Bacterial disease Submarket Forecast 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 26. Bacterial disease Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario V)
Figure 27. Bacterial disease Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 28. Bacterial disease Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 29. Bacterial disease Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 30. Anti-Infective Vaccines Submarket Forecast by end user 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 31. Anti-Infective Vaccines Submarket Forecast by end user 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 32. Anti-Infective Vaccines Submarket Forecast by end user 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 33. Anti-Infective Vaccines Submarket Forecast by end user 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 34. Anti-Infective Vaccines Submarket Forecast by end user 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 35. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 36. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario V)
Figure 37. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 38. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 39. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 40. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (Sales US$M, Global AGR %)
Figure 41. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure42. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 43. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 44. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 45. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %)
Figure 51. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %)
Figure 56. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 61. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 62. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 63. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 64. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 65. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 66. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 67. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 68. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 69. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 70. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %)
Figure 71. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 72. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 73. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 74. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 75. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M)
Figure 76. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario V)
Figure 77. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario U)
Figure 78. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario W)
Figure 79. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario L)
Figure 80. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (Before COVID)
Figure 81. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario V)
Figure 82. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario U)
Figure 83. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario W)
Figure 84. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario L)
Figure 85. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (Before COVID)
Figure 86. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 87. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 88. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 89. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 90. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 91. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 92. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 93. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 94. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 95. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 98. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %)
Figure 101. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 102. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 103. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 104. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 105. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %)
Figure 106. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 107. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 108. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 109. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 110. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 111. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 112. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 113. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 114. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 115 Asia-Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (Before COVID)
Figure 116. Asia-Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario V)
Figure 117. Asia-Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario U)
Figure 118. Asia-Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario W)
Figure 119. Asia-Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario L)
Figure 120. Asia-Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M)
Figure 121. Asia-Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario V)
Figure 122. Asia-Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario U)
Figure 123. Asia-Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario W)
Figure 124. Asia-Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario L)
Figure 125. Asia-Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M)
Figure 126. Asia-Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 127. Asia-Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 128. Asia-Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 129. Asia-Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 130. Asia-Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Asia-Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 132. Asia-Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 133. Asia-Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 134. Asia-Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 135. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %)
Figure 136. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138 China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %)
Figure 141. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 142. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 143. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 144. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 145. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 146. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 147. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 148. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 149. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 150. Rest of APAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 151. Rest of APAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 152 Rest of APAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 153. Rest of APAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 154. Rest of APAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 155. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M)
Figure 156. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario V)
Figure 157. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario U)
Figure 158. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario W)
Figure 159. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario L)
Figure 160. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M)
Figure 161. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario V)
Figure 162 Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M)
Figure 166. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Rest of Middle East Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %)
Figure 171. Rest of Middle East Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 172. Rest of Middle East Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 173. Rest of Middle East Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 174. Rest of Middle East Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 175. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M)
Figure 176. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario V)
Figure 177. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario U)
Figure 178. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario W)
Figure 179. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario L)
Figure 180. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M)
Figure 181. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario V)
Figure 182. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario U)
Figure 183. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario W)
Figure 184. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario L)
Figure 185. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M)
Figure 186. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 187. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 188. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 189. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 190. Rest of Latin America Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %)
Figure 191. Rest of Latin America Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 192. Rest of Latin America Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 193. Rest of Latin America Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 194. Rest of Latin America Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 195. Porter’s Five Force Analysis
Companies Mentioned
1. Pfizer Inc.
2. Merck & Co.
3. Sanofi Pasteur Inc.
4. Teva Pharmaceutical Industries Ltd.
5. GlaxoSmithKline Biologicals,
6. Emergent Biosolutions Inc.
7. AstraZeneca
8. Organon Teknika Corp LLC,
9. Emergent BioDefense Operations Lansing Inc.,
10. MedImmune LLC,
11. Novartis Vaccines
12. Serum Institute Of India Pvt. Ltd.
13. Protein Sciences Corporation
14. Diagnostics Ltd.
15. Intercell Biomedical,
16. MassBiologics,
17. Barr Labs, Inc.,
18. Organon Teknika Co.,
19. GlaxoSmithKline Biologicals,
20. CSL Ltd.,
21. ID Biomedical Co.,
22. Berna Biotech AG
23. Abbott Laboratories
24. Murex Corp.
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Anti-Infective Vaccines Market
2.1. Anti-Infective Vaccines Market Definition
2.2. By Product type Submarkets Definitions
2.3. By Disease type Submarkets Definitions
2.4. By End User Submarkets Definitions
3. Anti-Infective Vaccines Market Overview
3.1. Global Anti-Infective Vaccines Market Size and Forecast by Region
3.2. Global Anti-Infective Vaccines Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising Awareness for Infectious Diseases.
3.3.1.2. Priority Review Vouchers (PRVs), Development of New Vaccines for Infectious Diseases.
3.3.1.3. Rising Prevalence of Infectious Diseases.
3.3.2. Market Restraints/Challenges
3.3.2.1. High Cost Associated With R&D
3.3.2.2. Inadequate Funding of Healthcare in Developing Countries
3.3.3. Opportunities
3.3.3.1. Increasing Old Age Population.
3.3.3.2. Growing Health Awareness Among Population
3.3.3.3. Rising Disposable Income in Emerging Economies
3.3.3.4. Increasing Demand of Anti -Infective Vaccine Market
3.3.4. Global Anti-Infective Vaccines Market: Trends
3.3.4.1. Increasing Immunization Programmes.
3.3.4.2. Advancement in Healthcare Sector.
3.3.5. Porter’s Five Forces Analysis
3.3.5.1. Competitive Rivalry
3.3.5.2. Supplier Power
3.3.5.3. Buyer Power
3.3.5.4. Threat of Substitution
3.3.5.5. Threat of New Entry
4. Global Anti-Infective Vaccines Market Analysis and Forecast 2021-2031, by Product type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Live/attenuated Vaccines
4.1.1.1. Provides lifelong immunity one or two doses.
4.2. Inactivated Vaccines
4.2.1.1. Easy to store and freeze dried.
4.3. Conjugate vaccines
4.3.1.1. Low risk of adverse reaction.
4.4. toxoid vaccines
4.4.1.1. specifically used for Diphtheria and Tetanus.
4.5. Others
5. Global Anti-Infective Vaccines Market Analysis and Forecast, 2021-2031 by Disease type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Bacterial diseases
5.1.1.1. Tuberculosis vaccine
5.1.1.2. Tuberculosis is the leading cause of death among women.
5.1.1.3. Typhoid vaccine
5.1.1.4. Increasing typhoid in developing countries.
5.1.1.5. Diphtheria and Tetanus vaccines
5.1.1.6. DTaP vaccine, DT vaccine, Tdap vaccine and Td vaccine protects from Diphtheria and tetanus.
5.1.1.7. Others
5.1.2. Viral Diseases
5.1.2.1. Influenza vaccine
5.1.2.2. High risk of influenzas among elderly.
5.1.2.3. Hepatitis vaccine
5.1.2.4. RECOMBIVAX HB vaccine prevents from infection caused by subtypes of hepatitis B virus.
5.1.2.5. Polio vaccine
5.1.2.6. Increasing awareness and immunization campaigns.
5.1.2.7. Others
6. Global Anti-Infective Vaccines Market Analysis and Forecast, 2021-2031 by end user (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Hospitals
6.1.1.1. Increasing hospitalization among elderly due to risk infectious diseases.
6.1.2. Clinics
6.1.2.1. Rising adoption of Anti-Infective Vaccines in clinics & hospitals
6.1.3. Others
7. North America Anti-Infective Vaccines Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Anti-Infective Vaccines Market Size and Forecast by Product type
7.2.1. Live/attenuated Vaccines Submarket Expected to Grow at Significant Rate
7.3. North America Anti-Infective Vaccines Market Size and Forecast by Disease type
7.3.1. Bacterial disease Submarket to Grow at Significant Rate
7.4. North America Anti-Infective Vaccines Market Size and Forecast by end user
7.4.1. Hospitals Submarket to Grow at Significant Rate
7.5. U.S. Anti-Infective Vaccines Market
7.5.1. Developed Healthcare System.
7.6. Canada Anti-Infective Vaccines Market
7.6.1. Growing demand for infectious diseases vaccine.
8. Europe Anti-Infective Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Anti-Infective Vaccines Market Size and Forecast by Product type
8.2.1. Live/attenuated Vaccines Submarket Expected to Grow at Significant Rate
8.3. Europe Anti-Infective Vaccines Market Size and Forecast by Disease type
8.3.1. Bacterial disease Submarket to Grow at Significant Rate
8.4. Europe Anti-Infective Vaccines Market Size and Forecast by end user
8.4.1. Hospitals Submarket to Grow at Significant Rate
8.5. UK Anti-Infective Vaccines Market
8.5.1. Increasing multidrug-resistant among tuberculosis patients.
8.6. Germany Anti-Infective Vaccines Market
8.6.1. Surging demand for anti-infective vaccine in the region.
8.7. France Anti-Infective Vaccines Market
8.7.1. Presence of key market players are expected to drive market growth.
8.8. Rest of Europe Anti-Infective Vaccines Market
9. Asia Pacific Anti-Infective Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Anti-Infective Vaccines Market Size and Forecast by Product type
9.2.1. Live/attenuated Vaccines Submarket Expected to Grow at Significant Rate
9.3. Asia Pacific Anti-Infective Vaccines Market Size and Forecast by Disease type
9.3.1. Bacterial disease Submarket to Grow at Significant Rate
9.4. Asia Pacific Anti-Infective Vaccines Market Size and Forecast by end user
9.4.1. Hospitals Submarket to Grow at Significant Rate
9.5. China Anti-Infective Vaccines Market
9.5.1. Rising elderly population
9.6. India Anti-Infective Vaccines Market
9.6.1. Prevalence of infectious diseases.
9.7. Japan Anti-Infective Vaccines Market
9.7.1. Increasing healthcare awareness
9.8. Rest of Asia Pacific Anti-Infective Vaccines Market
10. Latin America Anti-Infective Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Anti-Infective Vaccines Market Size and Forecast by Product type
10.2.1. Live/attenuated Vaccines Submarket Expected to Grow at Significant Rate
10.3. Latin America Anti-Infective Vaccines Market Size and Forecast by Disease type
10.3.1. Bacterial disease Submarket to Grow at Significant Rate
10.4. Latin America Anti-Infective Vaccines Market Size and Forecast by end user
10.4.1. Brazil Anti-Infective Vaccines Market
10.4.1.1. Increasingly risk for acute respiratory infections.
10.4.2. Mexico Anti-Infective Vaccines Market
10.4.2.1. Prevalence of infectious diseases.
10.4.3. Rest of Latin America Anti-Infective Vaccines Market
10.4.3.1. Increasing government initiatives for immunization.
11. MEA Anti-Infective Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Anti-Infective Vaccines Market Size and Forecast by Product type
11.2.1. Live/attenuated Vaccines Submarket Expected to Grow at Significant Rate
11.3. MEA Anti-Infective Vaccines Market Size and Forecast by Disease type
11.3.1. Bacterial disease Submarket to Grow at Significant Rate
11.4. MEA Anti-Infective Vaccines Market Size and Forecast by end user
11.5. South Africa Anti-Infective Vaccines Market
11.5.1.1. Increasing risk of HIV in the population.
11.6. Rest of MEA Anti-Infective Vaccines Market
11.6.1.1. Increasingly healthcare awareness and vaccination for infectious diseases.
12. Companies in the Anti-Infective Vaccines Market
12.1. Pfizer Inc.
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2020)
12.1.3.1. Net Revenue
12.1.3.2. Gross Profit
12.1.3.3. Geographical Revenue, 2020
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2020)
12.2. Merck & Co.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Gross Profit
12.2.3.3. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. Sanofi Pasteur Inc.
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. Teva Pharmaceutical Industries Ltd.
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. GlaxoSmithKline Biologicals,
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Emergent Biosolutions Inc.
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Gross Profit
12.6.3.3. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. AstraZeneca
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Gross Profit
12.7.3.3. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. Organon Teknika Corp LLC,
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Gross Profit
12.8.3.3. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Emergent BioDefense Operations Lansing Inc.
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Gross Profit
12.9.3.3. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. MedImmune LLC,
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Gross Profit
12.10.3.3. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Anti-Infective Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Anti-Infective Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Anti-Infective Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Anti-Infective Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Anti-Infective Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Anti-Infective Vaccines Market Drivers & Restraints 2021
Table 7. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Conjugate vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Conjugate vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Toxoid vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Toxoid vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Toxoid vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Toxoid vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Toxoid vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Other Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Other Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Other Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Other Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Other Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32 .Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 33. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Bacterial disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Bacterial disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Bacterial disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Bacterial disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Bacterial disease Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Tuberculosis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Tuberculosis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Tuberculosis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Tuberculosis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Tuberculosis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Typhoid vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Typhoid vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Typhoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Typhoid vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Typhoid vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Diphtheria and Tetanus Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Diphtheria and Tetanus Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Diphtheria and Tetanus Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Diphtheria and Tetanus Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Diphtheria and Tetanus Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Viral Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Viral Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Viral Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Viral Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Viral Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Influenza vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Influenza vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Influenza vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Influenza vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Influenza vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Hepatitis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Hepatitis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74 Hepatitis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Hepatitis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Hepatitis vaccine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Polio Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Polio Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table79. Polio Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Polio Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Polio Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Anti-Infective Vaccines Market Forecast by end user 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Anti-Infective Vaccines Market Forecast by end user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Anti-Infective Vaccines Market Forecast by end user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Anti-Infective Vaccines Market Forecast by end user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Anti-Infective Vaccines Market Forecast by end user 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Hospitals Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Clinics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 120. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 121. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 122. North America Anti-Infective Vaccines Market Forecast by End User2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 123. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 124. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 125. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 126. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 127. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 128. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 129. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 130. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 131. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 132. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 133. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 134. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 135. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 136. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 137. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 138. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 139. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 140. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 141. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 142. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 143. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 144. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 145. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 146. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 147. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 148. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 149. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 150. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 151. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 152. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 153. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 154. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 155. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 156. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 157. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 158. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 159. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 160. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 161. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 162. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 163. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 164. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 165. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 166. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 167. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 168. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 169. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 170. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 171. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 172. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 173. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %CAGR %) (Before COVID)
Table 174.FranceAnti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %CAGR %), (COVID - Scenario W)
Table 175. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 176. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 177. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 178. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 179. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 180. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 181. Asia Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 182. Asia Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 183. Asia Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 184. Asia Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 185. Asia Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 186. Asia Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 187. Asia Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 188. Asia Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 189. Asia Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 190. Asia Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 191. Asia Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 192. Asia Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 193. Asia Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 194. Asia Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 195. Asia Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 196. Asia Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 197. Asia Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198. Asia Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199. Asia Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200. Asia Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216. RoAPAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217. RoAPAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218. RoAPAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219. RoAPAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220. RoAPAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224 Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231 Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232 Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 247. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248 Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251 Leading 10 Anti-Infective Vaccines Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 252. Pfizer Inc Profile 2020 (CEO, HQ, Founded, Website)
Table 253. Pfizer Inc Anti-Infective Vaccines Selected Recent Contracts 2020 (Date, Programme Type, Details)
Table 254. Pfizer Inc Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 255. Merck & Co. Profile 2020 (CEO, HQ, Founded, Website)
Table 256. Merck & Co Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 257. Sanofi Pasteur Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 258. Sanofi Pasteur Inc. Anti-Infective Vaccines Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 259. Sanofi Pasteur Inc. Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 260. Teva Pharmaceutical Industries Ltd Profile 2020 (CEO, HQ, Founded, Website)
Table 261. Teva Pharmaceutical Industries Ltd Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 262. Teva Pharmaceutical Industries Ltd Anti-Infective Vaccines Parasiticides Product Offering (Segment, Product Offerings)
Table 263. GlaxoSmithKline Biologicals, Profile 2020 (CEO, HQ, Founded, Website)
Table 264. GlaxoSmithKline Biologicals Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 265. Emergent Biosolutions Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 266. Emergent Biosolutions Inc Anti-Infective Vaccines Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 267 Emergent Biosolutions Inc Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 268. AstraZeneca Profile 2020 (CEO, HQ, Founded, Website)
Table 269. AstraZeneca. Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 270. Organon Teknika Corp LLC, Profile 2020 (CEO, HQ, Founded, Website)
Table 271. Organon Teknika Corp LLC, Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 272. Emergent BioDefense Operations Lansing Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 273. Emergent BioDefense Operations Lansing Inc.Anti-Infective Vaccines Product Offering (Segment, Product Offerings)
Table 274. MedImmune LLC Profile 2020 (CEO, Total Company Sales US$m, HQ, Founded, No. of Employees, Ticker, Website)
Table 275. MedImmune LLC Total Company Sales 2015-2019 (US$m, AGR %)
Table 276. MedImmune LLC Product Offering (Segment, Product Offerings)
Table 277. Other Companies Involved in the Anti-Infective Vaccines Market (Company, Location)
LIST OF FIGURES
Figure 1. Anti-Infective Vaccines Market Type Overview
Figure 2. Anti-Infective Vaccines Market By Product type Overview
Figure 3. Anti-Infective Vaccines Market By Disease type Overview
Figure4. Anti-Infective Vaccines Market End User Overview
Figure 5 Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Anti-Infective Vaccines Submarket Forecast by Product type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 16. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID – Scenario V)
Figure 17. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 18. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 19. Live/attenuated Vaccines Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 20. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Anti-Infective Vaccines Submarket Forecast by Disease type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Bacterial disease Submarket Forecast 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 26. Bacterial disease Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario V)
Figure 27. Bacterial disease Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 28. Bacterial disease Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 29. Bacterial disease Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 30. Anti-Infective Vaccines Submarket Forecast by end user 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 31. Anti-Infective Vaccines Submarket Forecast by end user 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 32. Anti-Infective Vaccines Submarket Forecast by end user 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 33. Anti-Infective Vaccines Submarket Forecast by end user 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 34. Anti-Infective Vaccines Submarket Forecast by end user 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 35. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 36. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario V)
Figure 37. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 38. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 39. Hospital Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 40. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (Sales US$M, Global AGR %)
Figure 41. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure42. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 43. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 44. Regional Anti-Infective Vaccines Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 45. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %)
Figure 51. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. North America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %)
Figure 56. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. North America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 61. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 62. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 63. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 64. North America Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 65. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 66. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 67. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 68. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 69. US Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 70. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %)
Figure 71. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 72. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 73. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 74. Canada Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 75. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M)
Figure 76. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario V)
Figure 77. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario U)
Figure 78. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario W)
Figure 79. Europe Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario L)
Figure 80. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (Before COVID)
Figure 81. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario V)
Figure 82. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario U)
Figure 83. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario W)
Figure 84. Europe Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario L)
Figure 85. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (Before COVID)
Figure 86. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 87. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 88. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 89. Europe Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 90. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 91. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 92. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 93. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 94. Europe Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 95. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 98. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. UK Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %)
Figure 101. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 102. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 103. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 104. Germany Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 105. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %)
Figure 106. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 107. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 108. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 109. France Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 110. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 111. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 112. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 113. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 114. Rest of Europe Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 115 Asia-Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (Before COVID)
Figure 116. Asia-Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario V)
Figure 117. Asia-Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario U)
Figure 118. Asia-Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario W)
Figure 119. Asia-Pacific Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario L)
Figure 120. Asia-Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M)
Figure 121. Asia-Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario V)
Figure 122. Asia-Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario U)
Figure 123. Asia-Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario W)
Figure 124. Asia-Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario L)
Figure 125. Asia-Pacific Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M)
Figure 126. Asia-Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 127. Asia-Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 128. Asia-Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 129. Asia-Pacific Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 130. Asia-Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Asia-Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 132. Asia-Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 133. Asia-Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 134. Asia-Pacific Anti-Infective Vaccines Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 135. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %)
Figure 136. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138 China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. China Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %)
Figure 141. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 142. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 143. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 144. India Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 145. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 146. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 147. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 148. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 149. Japan Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 150. Rest of APAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 151. Rest of APAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 152 Rest of APAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 153. Rest of APAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 154. Rest of APAC Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 155. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M)
Figure 156. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario V)
Figure 157. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario U)
Figure 158. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario W)
Figure 159. Middle East Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario L)
Figure 160. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M)
Figure 161. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario V)
Figure 162 Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Middle East Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M)
Figure 166. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Middle East Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Rest of Middle East Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %)
Figure 171. Rest of Middle East Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 172. Rest of Middle East Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 173. Rest of Middle East Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 174. Rest of Middle East Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 175. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M)
Figure 176. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario V)
Figure 177. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario U)
Figure 178. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario W)
Figure 179. Latin America Anti-Infective Vaccines Market Forecast by Product type 2021-2031 (US$M) (COVID - Scenario L)
Figure 180. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M)
Figure 181. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario V)
Figure 182. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario U)
Figure 183. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario W)
Figure 184. Latin America Anti-Infective Vaccines Market Forecast by Disease type 2021-2031 (US$M) (COVID - Scenario L)
Figure 185. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M)
Figure 186. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 187. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 188. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 189. Latin America Anti-Infective Vaccines Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 190. Rest of Latin America Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %)
Figure 191. Rest of Latin America Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 192. Rest of Latin America Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 193. Rest of Latin America Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 194. Rest of Latin America Anti-Infective Vaccines Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 195. Porter’s Five Force Analysis
Companies Mentioned
1. Pfizer Inc.
2. Merck & Co.
3. Sanofi Pasteur Inc.
4. Teva Pharmaceutical Industries Ltd.
5. GlaxoSmithKline Biologicals,
6. Emergent Biosolutions Inc.
7. AstraZeneca
8. Organon Teknika Corp LLC,
9. Emergent BioDefense Operations Lansing Inc.,
10. MedImmune LLC,
11. Novartis Vaccines
12. Serum Institute Of India Pvt. Ltd.
13. Protein Sciences Corporation
14. Diagnostics Ltd.
15. Intercell Biomedical,
16. MassBiologics,
17. Barr Labs, Inc.,
18. Organon Teknika Co.,
19. GlaxoSmithKline Biologicals,
20. CSL Ltd.,
21. ID Biomedical Co.,
22. Berna Biotech AG
23. Abbott Laboratories
24. Murex Corp.
Companies Profiled in the Report
1. Pfizer Inc.
2. Merck & Co.
3. Sanofi Pasteur Inc.
4. Teva Pharmaceutical Industries Ltd.
5. GlaxoSmithKline Biologicals,
6. Emergent Biosolutions Inc.
7. Astrazeneca
8. Organon Teknika Corp LLC,
9. Emergent BioDefense Operations Lansing Inc.
10. MedImmune LLC,
11. Novartis Vaccines
12. Serum Institute Of India Pvt. Ltd.
13. Protein Sciences Corporation
14. Diagnostics Ltd.
List of Companies Mentioned in the Report:
1. Pfizer Inc.
2. Merck & Co.
3. Sanofi Pasteur Inc.
4. Teva Pharmaceutical Industries Ltd.
5. GlaxoSmithKline Biologicals,
6. Emergent Biosolutions Inc.
7. AstraZeneca
8. Organon Teknika Corp LLC,
9. Emergent BioDefense Operations Lansing Inc.,
10. MedImmune LLC,
11. Novartis Vaccines
12. Serum Institute of India Pvt Ltd.
13. Protein Sciences Corporation
14. Diagnostics Ltd.
15. Intercell Biomedical,
16. MassBiologics,
17. Barr Labs, Inc.,
18. Organon Teknika Co.,
19. GlaxoSmithKline Biologicals,
20. CSL Ltd.,
21. ID Biomedical Co.,
22. Berna Biotech AG
23. Abbott Laboratories
24. Murex Corp.
List of Organizations Mentioned in the Report
1. Companion Animal Parasite Council (CAPC)
2. United States Department of Agriculture
3. US Food & Drug Administration
4. US National Library of Medicine
5. National Institutes of Health
6. National Association for Biomedical Research
7. Center for Disease Control and Prevention CDC
8. US Center for Disease Control and Prevention
9. National Institute of Food and Agriculture (NIFA)
10. The Food & Agriculture Organisation
11. Center for Health Security
12. The History of Vaccines
13. Department of Medicine
14. The Infectious Diseases Working Party (AGIHO)
15. Therapeutics in Dermatology
16. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
17. World Health Organisation
18. National Institute on Aging
19. National Institutes of Health
20. U.S. Department of Health and Human Services
21. United Nations world population
22. Regulatory Affairs Professionals Society (RAPS)
1. Pfizer Inc.
2. Merck & Co.
3. Sanofi Pasteur Inc.
4. Teva Pharmaceutical Industries Ltd.
5. GlaxoSmithKline Biologicals,
6. Emergent Biosolutions Inc.
7. Astrazeneca
8. Organon Teknika Corp LLC,
9. Emergent BioDefense Operations Lansing Inc.
10. MedImmune LLC,
11. Novartis Vaccines
12. Serum Institute Of India Pvt. Ltd.
13. Protein Sciences Corporation
14. Diagnostics Ltd.
List of Companies Mentioned in the Report:
1. Pfizer Inc.
2. Merck & Co.
3. Sanofi Pasteur Inc.
4. Teva Pharmaceutical Industries Ltd.
5. GlaxoSmithKline Biologicals,
6. Emergent Biosolutions Inc.
7. AstraZeneca
8. Organon Teknika Corp LLC,
9. Emergent BioDefense Operations Lansing Inc.,
10. MedImmune LLC,
11. Novartis Vaccines
12. Serum Institute of India Pvt Ltd.
13. Protein Sciences Corporation
14. Diagnostics Ltd.
15. Intercell Biomedical,
16. MassBiologics,
17. Barr Labs, Inc.,
18. Organon Teknika Co.,
19. GlaxoSmithKline Biologicals,
20. CSL Ltd.,
21. ID Biomedical Co.,
22. Berna Biotech AG
23. Abbott Laboratories
24. Murex Corp.
List of Organizations Mentioned in the Report
1. Companion Animal Parasite Council (CAPC)
2. United States Department of Agriculture
3. US Food & Drug Administration
4. US National Library of Medicine
5. National Institutes of Health
6. National Association for Biomedical Research
7. Center for Disease Control and Prevention CDC
8. US Center for Disease Control and Prevention
9. National Institute of Food and Agriculture (NIFA)
10. The Food & Agriculture Organisation
11. Center for Health Security
12. The History of Vaccines
13. Department of Medicine
14. The Infectious Diseases Working Party (AGIHO)
15. Therapeutics in Dermatology
16. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
17. World Health Organisation
18. National Institute on Aging
19. National Institutes of Health
20. U.S. Department of Health and Human Services
21. United Nations world population
22. Regulatory Affairs Professionals Society (RAPS)
Download sample pages
Complete the form below to download your free sample pages for Anti-infective Vaccines Market Report to 2031Download sample pages
Complete the form below to download your free sample pages for Anti-infective Vaccines Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Would you like to get the latest Visiongain pharma reports catalogue?
What are the dynamic growth sectors? where are the regional business opportunities?
Which technologies will prevail and who are the leading companies succeeding in these sectors and why?
If you want definitive answers to business critical questions, discover Visiongain’s full range of business intelligence reports.
If so, please email Sara Peerun on sara.peerun@visiongain.com or call her today on +44 (0) 20 7549 9987
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.Click here to ‘Like’ our Facebook page https://www.facebook.com/V.G.Pharma/
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Cancer Diagnostics Market Report 2021-2031
Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.
19 April 2021
Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030
The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.
12 April 2021
Visiongain Publishes Cell-Based Assays Market Report to 2030
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
09 April 2021
Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
06 April 2021
